Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States

References

• National Cancer Institute. SEER Cancer Statistics Review 1975-2008. SEER, 2011. http://seer.cancer.gov/csr/1975_2008/. Accessed October 24, 2011
   Google Scholar
• Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492–502
   PubMed Web of Science ®Google Scholar
• Hannemann J, Kristel P, van Tinteren H, et al. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 2006;95:1334–41
   PubMedGoogle Scholar
• National Comprehensive Cancer Network I. NCCN clinical practice guidelines in oncology: breast cancer. 2011;NCCN.org. Accessed October 5, 2011
   Google Scholar
• Gonzalez-Angulo A, Morales-Vasquez F, Hortobagyi G. Overview of resistance to systematic therapy in patients with breast cancer. Madame Curie Bioscience Database [Internet]. Austin, TX: Landes Bioscience, 2000
   Google Scholar
• Johnston S. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:1979–87
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520–9
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Approved label for everolimus. FDA, Silver Spring, MD, 2012.   http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed on September 13, 2012
   Google Scholar
• US Census Bureau. Table 1: intercensal estimates of the resident population by sex and age for the United States: April 1, 2000 to July 1, 2010 (US-EST00INT-01). US Census Bureau, Washington, DC, 2010
   Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047–59
   PubMed Web of Science ®Google Scholar
• Ho J, Zhang L, Todorova L, et al. Budget impact analysis of ixabepilone used according to FDA labeling in treatment-resistant metastatic breast cancer. J Manag Care Pharm 2009;15:467–75
   PubMed Web of Science ®Google Scholar
• Drug Topics RedBook. ReadyPrice Software, 2011. Access through MICROMEDEX 2.0; Thomson Reuters (Healthcare) Inc. Montvale, NJ. http://thomsonreuters.com/products_services/healthcare/healthcare_products/clinical_deci_support/micromedex_clinical_evidence_sols/med_safety_solutions/red_book/. Accessed February 22, 2012
   Google Scholar
• Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664–70
   PubMed Web of Science ®Google Scholar
• Thürlimann B, Hess D, Köberle D, et al. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004;85:247–54
   PubMed Web of Science ®Google Scholar
• Klepser DG, Huether JR, Handke LJ, et al. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance. J Manag Care Pharm 2007;13:765–77
   PubMed Web of Science ®Google Scholar
• Mansley EC, Carroll NV, Chen KS, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III. Value Health 2010;13:14–17
   PubMed Web of Science ®Google Scholar
• BLS data series. Consumer Price Index - All Urban Consumers. Washington, DC, 2012
   Google Scholar
• Lamerato L, Havstad S, Gandhi S, et al. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer 2006;106:1875–82
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. Baltimore, MD. Statewide average operating cost-to-charge ratios for urban and rural hospitals (case weighted) March 2000. Medicare program: changes to the hospital inpatient prospective payment systems and fiscal year 2001 rates. http://www.federalregister.gov/articles/2000/08/01/00-19108/medicare-program-changes-to-the-hospitalinpatient-prospective-payment-systems-and-fiscal-year-2001#t-37. Accessed November 21, 2012
   Google Scholar
• Hortobagyi GN, Piccart M, Burris H, et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 Phase III Trial. Thirty-Fourth Annual CTRC-AACR San Antonio Breast Cancer Symposium -- Dec 6--10, 2011; San Antonio, TX, SABCS abstracts 2011
   Google Scholar
• Ershler WB, Chen K, Reyes EB, et al. Economic burden of patients with anemia in selected diseases. Value Health 2005;8:629–38
   PubMed Web of Science ®Google Scholar
• Dial E, Fournier A, Moyneur E, et al. Frequency and cost of adverse events in renal cell carcinoma (RCC) patients receiving angiogenesis inhibitor therapies. J Clin Oncol 2008;26(Suppl):abstr 14609
   Google Scholar
• Mauskopf JA, Sullivan SD, Anneman SL, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices - budget impact analysis. Value Health 2007;10:336–47
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Approved label for exemestane. FDA, Silver Spring, MD, 2011. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed October 26, 2011
   Google Scholar
• U.S. Food and Drug Administration. Approved label for Faslodex (Fulvestrant). FDA, Silver Spring, MD, 2011. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed October 26, 2011
   Google Scholar
• U.S. Food and Drug Administration. Approved label for tamoxifen. FDA, Silver Spring, MD, 2011. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed October 26, 2011
   Google Scholar